Fostamatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), HIRA (South Korea) and NICE (England), among others, recommended or restricted fostamatinib, while CIPM (Spain) did not recommend it.
Where fostamatinib met resistance it was usually narrowed rather than refused: 3 of 6 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The record spans 4.2 years, opening at G-BA (Germany) on 17 Dec 2020 and running to 6 Mar 2025.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PBAC (Australia) and PHARMAC (New Zealand) among them — hold no record for fostamatinib at all.
G-BA (Germany) was first to assess fostamatinib, on 17 Dec 2020; HIRA (South Korea) did not open a file until 6 Mar 2025 — a wide spread of 4.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 8 dated records fall in 2022 alone.
Restriction is doing real work here: 3 of 6 decisive outcomes narrowed fostamatinib to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), NICE (England) and SMC (Scotland).
8 of the 18 agencies in this archive hold a record for fostamatinib.
The full ledger for fostamatinib reads 3 restricted, 2 recommended, 1 advice and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 6 Mar 2025 | 만성 면역 혈소판 감소증 (ITP) | reimbursable only at the evaluated price | source |
| DMC (Denmark) | 20 Dec 2022 | Kronisk immuntrombocytopeni | Anbefalet | source |
| ZIN (Netherlands) | 6 Dec 2022 | GVS-advies fostamatinib (Tavlesse®) voor de behandeling van chronische immuun trombocytopenie (ITP) | advice published (GVS) | source |
| NICE (England) | 19 Oct 2022 | NICE TA835 | recommended (optimised) | source |
| NYE METODER (Norway) | 28 Aug 2022 | Behandling av kronisk immunologisk trombocytopeni hos voksne pasienter som er refraktære overfor annen behandling | introduced | source |
3 further decisions for fostamatinib, across 3 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- emicizumab — same ATC class B02B — Antihemorrhagics
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- marstacimab — same ATC class B02B — Antihemorrhagics
Coverage: 8 decisions for fostamatinib from 8 agencies, 2020 to 2025. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.